SCHEMBL3851454

SCHEMBL3851454

CCOC(=O)c1c(O)c(-c2cccc(OC)c2)nn(Cc2ccccc2C(F)(F)F)c1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.47
KDM4E B2RXH2 4/20 0.47
HPGD P15428 3/20 0.47
HSD17B10 Q99714 2/20 0.47
TP53 P04637 1/20 0.47
MAPT P10636 3/20 0.42
THRB P10828 1/20 0.42
NPBWR1 P48145 1/20 0.42
KMT2A Q03164 4/20 0.42
MEN1 O00255 3/20 0.42
NPSR1 Q6W5P4 2/20 0.42
LMNA P02545 1/20 0.42
GAA P10253 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
SLC16A3 O15427 6/20 0.40
SLC16A1 P53985 6/20 0.40
MCTS1 Q9ULC4 3/20 0.40
DGAT2 Q96PD7 1/20 0.40
CMA1 P23946 1/20 0.39
ALOX15 P16050 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3856473 0.87 SLC16A3 (0.50) ALDH1A1KDM4EHPGDHSD17B10TP53
SCHEMBL3847891 0.86 ALDH1A1 (0.41) ALDH1A1KDM4ENPBWR1LMNAL3MBTL1
SCHEMBL3854878 0.85 ALDH1A1 (0.46) ALDH1A1KDM4EHPGDTP53KMT2A
SCHEMBL3847819 0.85 ALDH1A1 (0.38) ALDH1A1KDM4ENPBWR1LMNAL3MBTL1
SCHEMBL3849682 0.84 TP53 (0.49) ALDH1A1KDM4ETP53NPBWR1KMT2A
SCHEMBL3857680 0.80 KDM4E (0.43) ALDH1A1KDM4ENPBWR1KMT2AMEN1
SCHEMBL3846850 0.79 KDM4E (0.45) ALDH1A1KDM4ENPBWR1NPSR1LMNA
SCHEMBL3846803 0.77 MAPT (0.46) ALDH1A1KDM4EHPGDTP53MAPT
SCHEMBL3849224 0.75 ALDH1A1 (0.50) ALDH1A1KDM4EMAPTKMT2AMEN1
SCHEMBL3851363 0.73 PDE4A (0.61) ALDH1A1KDM4EMAPTKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2889289-A1 Pyridazine-dione N-substituted glycine derivatives as HIF hydroxylase inhibitors GlaxoSmithKline LLC (US) 2015-07-01 EP disclosed
US-RE44613-E1 N-substituted glycine derivatives: hydroxylase inhibitors GLAXOSMITHKLINE LLC (US) 2013-11-26 US disclosed
US-7608621-B2 Such as n-{[2-[(4-bromo-2-fluorophenyl)methyl]-5-hydroxy-6-(1-methylethyl)-3-oxo-2,3-dihydro-4-pyridazinyl]carbonyl}glycine; anemia; increasing erythropoietin production SMITHKLINE BEECHAM, CORP. (US) 2009-10-27 US disclosed
US-20080214549-A1 N-Substituted Glycine Derivatives: Hydroxylase Inhibitors GLAXOSMITHKLINE LLC 2008-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214549-A1 N-Substituted Glycine Derivatives: Hydroxylase Inhibitors EGLN2, EGLN3, HIF1AN ALDH1A1 564/4885KDM4E 527/4885HPGD 32/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.